Credit: Shutterstock photoHealthcare shares were generally mixed in pre-market trade on Thursday.
In healthcare stocks news, analysts at Stifel Nicolaus have upgraded their coverage of development-stage biopharmaceutical company Clovis Oncology Inc. ( CLVS ) to a buy rating from a hold.
The firm set its price target on the stock at $50 a share, which represents a potential upside of 26% from its current market price.
Shares of CLVS have gained more than 3% to trade at $39.67 in today's early session, but remain in the low end of their 52-week trading range of $36.11 - $93.33.
And, Halozyme Therapeutics ( HALO ) said the FDA removed the clinical hold on patient enrollment and dosing of PEGPH20 in the ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer permitting the study to resume under a revised protocol.
Finally, Actavis ( ACT ) entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or narcolepsy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
